Tianjin Ringpu Bio-Technology (300119) Stock Overview

Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, drug preparation, functional additives, and veterinary biological products. The company provides vaccines and drugs for poultry, waterfowl, livestock, and other animals; pet products comprising insect repellent series, ear products, nutritional supplements, anesthesia for surgery, anti-infective, antiviral, benazepril hydrochloride chewable tablets, meloxicam tablets, benzyl trimethylammonium chloride solution, etc.; and waterfowl products, including duck tempusu live/inactivated vaccine, gosling plague refined egg yolk antibody, duck infectious serositis inactivated vaccine, duck viral hepatitis refined egg yolk antibody, duck plague live vaccine, swine fever vaccine, etc. It offers ruminant products comprising cefquinome sulfate breast injection, ceftiofur hydrochloride injection, foot bath, nitrofenac injection, etc.; livestock products comprising ceftiofur injection, florfenicol powder, compound amoxicillin powder, tyvalin tartrate premix, carbasalate calcium soluble powder, florfenicol injection, etc.; and APIs comprising tilmicosin, tilmicosin phosphate, totrazuli, florfenicol, warnemulin hydrochloride, etc. In addition, the company provides potassium persulfate complex powder, concentrated glutaraldehyde solution, decyl ammonium bromide solution, and glutaraldehyde decyl ammonium bromide solution. Tianjin Ringpu Bio-Technology Co.,Ltd. was founded in 1998 and is headquartered in Tianjin, China.